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Vitamin E δ-tocotrienol triggers 
endoplasmic reticulum stress-
mediated apoptosis in human 
melanoma cells
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Malignant melanoma is the leading cause of death from skin cancer. Drug toxicity and resistance 
represent a serious challange for melanoma treatments. Evidence demonstrates that natural 
compounds may play a crucial role in cancer prevention, growth and progression. Vitamin E tocotrienols 
(TT) were shown to possess antitumor activity. Here, we analyzed the effects of δ-TT on melanoma cell 
growth and the involvement of the endoplasmic reticulum (ER) stress in this activity. The experiments 
were performed on human melanoma cell lines, BLM and A375. δ-TT exerted a significant proapoptotic 
effect on both cell lines, involving the intrinsic apoptosis pathway; importantly, this compound did not 
affect the viability of normal human melanocytes. In melanoma cells, δ-TT exerted its antitumor effect 
through activation of the PERK/p-eIF2α/ATF4/CHOP, IRE1α and caspase-4 ER stress-related branches. 
Salubrinal, an inhibitor of the ER stress, counteracted the cytotoxic activity of δ-TT. In vivo experiments 
performed in nude mice bearing A375 xenografts evidenced that δ-TT reduces tumor volume and tumor 
mass; importantly, tumor progression was significantly delayed by δ-TT treatment. In conclusion, 
δ-TT exerts a proapoptotic activity on melanoma cells, through activation of the ER stress-related 
pathways. δ-TT might represent an effective option for novel chemopreventive/therapeutic strategies 
for melanoma.
Malignant melanoma is the deadliest skin cancer; its incidence has been increasing faster than any other cancer, 
with a 2.6% annual increase over the last decade1. The majority of melanomas are diagnosed in the early stage 
and are curable with surgical resection; however, the prognosis of late stage melanomas is still poor. Alkylating 
agents (dacarbazine and temozolomide) and cytokines (interferon-α and interleukin-2) represent the first treat-
ment options; however, resistance easily develops with serious side effects2. Targeted therapy was introduced in 
melanoma treatment. The V600E mutation (valine at codon 600 is substituted by glutamic acid) of the BRAF 
oncogene is present in approximately 50% of patients, leading to the activation of the mitogen-activated protein 
kinase (MAPK) pathway; on the other hand, about 30% of melanomas harbour the NRAS mutation, known to be 
associated with increased activation of both the MAPK and the phosphoinositide 3-kinase (PI3K)/Akt pathways3. 
Molecular targeted therapy consists of BRAF inhibitors, such as vemurafenib and dabrafenib, or MEK inhib-
itors, such as trametinib. These compounds were initially associated with positive clinical results; however, a 
rapid development of resistance was found to occur in most patients4. Immune checkpoint inhibitors were devel-
oped for the treatment of aggressive melanomas. Ipilimumab, a monoclonal antibody against the CTLA-4 T 
lymphocyte receptor, and nivolumab and pembrolizumab, monoclonal antibodies against the inhibitory pro-
grammed cell death-1 (PD-1) receptor expressed on activated T cells, were approved by the US Food and Drug 
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Administration (FDA)4. However, these compounds did not provide the expected improvement on overall sur-
vival, being accompanied by severe toxicity5. Based on these disappointing observations, combination treatments 
targeting different intracellular pathways are currently investigated as potential effective therapeutic strategies for 
aggressive melanomas6.
The role of natural dietary components in cancer growth and progression has become a very popular subject. 
About 36% of the small molecule compounds approved by FDA between 1999 and 2008 are natural products or 
their derivatives7. Moreover, the role of dietary factors in preventing cancers was investigated in a large body of 
epidemiological studies. Natural compounds, such as epigallocatechin-3-gallate (EGCG), resveratrol, lycopene, 
polyunsaturated omega-3 fatty acids (PUFA) and genistein, were reported to exert antitumor effects on several 
cancer cell lines8,9. These compounds were also shown to possess chemopreventive activity and to potentiate the 
antitumor effects of standard treatments10,11.
Vitamin E is a family composed of α , β , δ and γ -tocopherols and the corresponding four tocotrienols (TTs). 
TTs, in particular, were widely shown to exert health-promoting effects in different chronic diseases, based on 
their powerful neuroprotective, antiinflammatory, antioxidant and cholesterol lowering potentials12,13. Evidence 
has also accumulated demonstrating the more potent anticancer effects of TTs (δ and γ -TT in particular) com-
pared with tocopherols in tumors14,15. The mechanisms of the antiproliferative properties of tocotrienols are still 
under investigation and they seem to involve different intracellular pathways16–19.
The endoplasmic reticulum (ER) stress response is a cellular process that can be triggered by different con-
ditions that cause imbalance in intracellular homeostasis. ER stress, which severely impairs protein folding, can 
be induced by different physiological and pathological conditions20, as well as by a number of compounds of 
synthetic or natural origins21,22. Cells react to ER stress with an initial defensive process, the so called unfolded 
protein response (UPR), aimed at restoring homeostasis by enhancing protein folding capacity23; however, in con-
ditions of severe stress, misfolded proteins accumulate in the ER ultimately triggering a set of prodeath programs 
(the yin and yang principle)21. Three major proteins are known to act as stress sensors in the ER: double-stranded 
RNA-dependent protein kinase PKR-like ER kinase (PERK), inositol-requiring enzyme 1α (IRE1α ), and activat-
ing transcription factor 6 (ATF6)24. In physiological conditions, these sensors are inactivated by the association 
with the chaperon protein immunoglobulin-heavy-chain-binding protein (BiP, also known as GRP78). Under 
severe ER stress, BiP dissociates from the sensors triggering their activation; each of these proteins is coupled with 
a cytosolic pathway and each pathway converges to apoptosis25–27. In particular, transcription factor ATF4, acti-
vated by the PERK/eIF2α pathway, stimulates the expression of the proapoptotic protein CHOP (C/EBP homol-
ogous protein, also called GADD153). IRE1α catalizes an unconventional splicing of the X box binding protein 
1 (XBP1). However, under severe ER stress, IRE1α leads to downstream activation of the JNK and p38 MAPK 
pathways, leading to the activation of apoptosis-related proteins, such as CHOP and caspase-426–28. It is recog-
nized that CHOP is a major player in mediating the ER stress-induced apoptosis pathways.
ER stress is implicated in the pathogenesis of a variety of diseases (neurodegeneration, inflammation, 
cancer)20,29–31. Emerging evidence indicates that pharmacological targeting of ER stress can represent an effective 
therapeutic strategy to treat tumors21,27,28. Different natural compounds have been shown to induce ER 
stress-mediated death in cancer cells32.
Here, we investigated the effects of δ -TT on melanoma cell growth, both in vitro and in vivo, and the involve-
ment of the ER stress signaling in its activity.
Results
δ-TT decreases cell viability and exerts a cytotoxic effect on melanoma cells. BLM and A375 
cells, or normal human melanocytes, were treated with δ -TT (5–20 μ g/ml) for 24 h or 48 h; cell viability was 
assessed by MTT assay. Figure 1a shows that the tocotrienol dose-dependently inhibited the number of viable 
melanoma cells at both time intervals, being significantly effective at 10–20 μ g/ml (Fig. 1a). These doses corre-
spond to those previously reported for the antitumor activity of tocotrienols in cancer cell lines33–35. Strikingly, the 
same treatment schedule did not affect the growth of human normal melanocytes at both time intervals (Fig. 1a).
To investigate whether δ -TT might induce melanoma cell death, BLM and A375 cells were treated with differ-
ent doses of δ -TT (5–20 μ g/ml) for 24 h, then floating (dying) and adherent (living) cells were harvested, stained 
with 0.4% of Trypan blue (1:1) and counted with an automated cell counter, differentiating from total, living and 
dead cells. Figure 1b shows that, in both BLM and A375 cells, δ -TT induced a dose-response effect with a signif-
icant reduction of total and viable cells, and a parallel significant increase of dead cells, stained with Trypan blue 
(Fig. 1b).
To confirm the cytotoxic effect of δ -TT on melanoma cells, a colony formation assay was performed. BLM 
and A375 cells were treated with δ -TT (20 μ g/ml) for 72 h and then, after withdrawal of the treatment, cells were 
left to grow for 7–10 days, dependently on the cell line-specific proliferation rate (36 h for BLM cells and 24 h for 
A375 cells), to assess: 1) the ability of the cells to proliferate forming colonies (dimensions of colonies); and 2) the 
survival of colony-forming cells (number of colonies). Crystal violet staining evidenced that control cells were 
able to grow and proliferate to form colonies. On the other hand, none of the treated cells survived upon δ -TT 
treatment and colony formation was completely prevented, indicating a cytotoxic, rather than a cytostatic, effect 
of this compound on melanoma cells (Fig. 1c).
δ-TT affects the expression of apoptosis-related proteins in melanoma cells. Apoptosis is highly 
dependent on the activation (cleavage) of caspases, such as the effector caspase-3, and their direct downstream 
targets, such as PARP (Poly (ADP-ribose) polymerase), involved in DNA repair. Activated caspase-3 cleaves this 
enzyme, preventing DNA damages repair and contributing to cell death. To verify whether δ -TT might induce 
apoptosis, cells were treated with different doses (10–20 μ g/ml) of δ -TT for 48 h or with 20 μ g/ml for 18–48 h. By 
Western blotting we could observe that the levels of cleaved caspase-3 increased after δ -TT treatment at the doses 
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of 15 and 20 μ g/ml in both BLM and A375 cells (Fig. 2a). A time-course increase of cleaved caspase-3 levels was 
also observed at the dose of 20 μ g/ml at all time intervals in both cell lines (Fig. 2b).
Figure 1. δ-TT decreases cell viability and exerts a cytotoxic effect on BLM and A375 melanoma cells, 
without affecting the growth of normal human melanocytes. (a) Melanoma cells and normal human 
melanocytes were treated with δ -TT (5–20 μ g/ml) for 24 or 48 h. Cell viability was then evaluated by MTT 
assay. (b) Melanoma cells were treated with δ -TT (5–20 μ g/ml) for 24 h. Total, live and dead cells were evaluated 
by Trypan blue exclusion assay. (c) Melanoma cells were treated with δ -TT (20 μ g/ml) for 72 h and then, after 
withdrawal of the treatment, were left to grow for 7–10 days, dependently on the cell line-specific proliferation 
rate. A colony-formation assay was performed to evaluate the ability of the cells to proliferate forming colonies 
(dimensions of the colonies) and the survival of colony-forming cells (number of colonies). Each experiment 
was repeated at least three times. Data in (a,b) represent mean values ± SEM and were analyzed by Bonferroni’s 
test after one-way analysis of variance. * p < 0.05 vs 0, controls.
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Western blot analyses were then performed to assess the activation of the apoptosis process, by verifying the 
cleavage of PARP. Accordingly to the time-course cleavage of caspase-3, cleavage of PARP occurred after the 
treatment of BLM and A375 cells with δ -TT (20 μ g/ml) for 18, 24 or 48 h (Fig. 2b).
δ-TT affects the expression/intracellular localization of proteins involved in the intrinsic apoptosis 
pathway in melanoma cells. Proteins, such as Bax and Bcl-2, are involved in the intrinsic apoptosis path-
way. An increased ratio between Bax (proapoptotic) and Bcl-2 (antiapoptotic) leads to the disruption of the mito-
chondrial outer membrane potential (MOMP) and to the release of cytochrome c. Figure 3a shows that, in BLM 
cells, an increased expression of Bax occurred after 18 and 24 h of treatment with δ -TT (20 μ g/ml); Bcl-2 expres-
sion was unaffected by the treatment. In A375 cells, δ -TT induced a reduction in Bcl-2 expression at 18–24 h; no 
changes in the expression levels of Bax were observed (Fig. 3a). A densitometric analysis has been performed on 
the protein bands shown in this Figure and the Bax/Bcl-2 ratios have been evaluated. The results obtained indicate 
that, in both cell lines, an increased Bax/Bcl-2 ratio occurs at 18 and 24 h of treatment, indicative of alterations in 
MOMP (Fig. 3a). In line with these observations, by immunofluorescence analysis, we found that δ -TT treatment 
(24 h) induced a different localization of cytochrome c, that was diffused in the cytosol and did not overlap with 
mitochondria (as evaluated by Mitotracker staining) (Fig. 3b), demonstrating that δ -TT induces cytochrome c 
release in both cell lines.
δ-TT increases the expression of ER stress-related proteins in melanoma cells. Experiments were 
performed to investigate whether δ -TT might induce ER stress-mediated apoptosis in melanoma cells. As a posi-
tive control, BLM cells were first treated with thapsigargin (TG, 1 μ M, for 1–24 h), the irreversible SERCA (sarco/
endoplasmic reticulum Ca2+-ATPase) inhibitor, that disrupts Ca2+ homeostasis and activates ER stress36; as the 
experimental model, BLM and A375 cells were treated with δ -TT (20 μ g/ml) for 1–24 h. By Western blotting 
we evaluated the expression levels of ER stress markers (BiP, p-eIF2α , eIF2α , PERK, IRE1α and PDI, protein 
disulfide isomerase, a Ca2+-dependent chaperon protein located in the ER lumen) and ER stress-related apoptosis 
markers (ATF4, CHOP and ERO1α , a target of CHOP, involved in the hyperoxidation of the ER environment, 
through generation of ROS). The expression of caspase-4 was also analyzed. Caspase-4 is the initiator caspase 
involved in the ER stress-induced apoptosis. Following ER stress procaspase-4 is cleaved (e.g. activated) to acti-
vate the effector caspase-3.
As expected, thapsigargin induced a significant, time-dependent, increase in the expression of all these ER 
stress-related markers in BLM melanoma cells (Fig. 4a). δ -TT induced an increase in the levels of BiP at 18–24 
in both BLM and A375 cells. PERK and IRE1α levels were increased at 18 h in BLM cells and at 18–24 h in A375 
Figure 2. δ-TT affects the expression of apoptosis-related proteins in BLM and A375 melanoma cells.  
(a) Melanoma cells were treated with δ -TT (10–20 μ g/ml) for 48 h. Western blot analysis was carried out with 
anti-caspase-3 (1:500) antibody. (b) Melanoma cells were treated with δ -TT (20 μ g/ml) for 18–48 h. Western 
blot analysis was carried out with anti-caspase-3 (1:500) and anti-PARP (1:1,000) antibodies. β -actin expression 
was evaluated as a loading control. 0, controls. One representative of three different experiments, for each of the 
analyses performed, is shown.
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cells, while p-eIF2α (but not the unphosphorylated form of the protein, eIF2α ) levels were increased at 18–24 h 
of treatment in both cell lines. The levels of the transcription factors ATF4 and CHOP were increased at 18–24 h 
in BLM cells and at 6–24 h in A375 cells. The expression of ERO1α was unaffected in BLM cells, while its increase 
was observed in A375 cells. On the other hand, the expression of the chaperone protein PDI was unaffected by the 
treatment with δ -TT in both cell lines (Fig. 4a). Cleaved caspase-4 levels were also increased by δ -TT treatment 
(Fig. 4a). This activation occurred at shorter time intervals than caspase-3 cleavage (see Fig. 2b), supporting its 
role in caspase-3 activation.
To investigate the intracellular localization of the key transcription factors involved in the ER stress process, 
BLM and A375 cells were treated with δ -TT (20 μ g/ml) for 18 h. Figure 4b shows that, in basal conditions, ATF4 
Figure 3. δ-TT affects the expression/intracellular localization of proteins involved in the intrinsic 
apoptosis pathway in BLM and A375 melanoma cells. (a) Melanoma cells were treated with δ -TT (20 μ g/ml) 
for 1–24 h. Western blot analysis was carried out with anti-Bcl-2 (1:1,000) and anti-Bax (1:500) antibodies.  
β -actin expression was evaluated as a loading control. One representative of three different experiments, for 
each of the analyses performed, is shown. A densitometric analysis of the bands obtained was performed and 
the relative Bax/Bcl-2 ratios in both cell lines were calculated. * p < 0.05 vs 0, controls (b) Melanoma cells 
were treated with δ -TT (20 μ g/ml) for 24 h and the intracellular localization of cytochrome c was evaluated by 
immunofluorescence analysis. Specifically, cells were incubated for 30 min with Mitotracker (250 nM), fixed and 
stained with cytochrome c antibody (1:50) followed by the FITC-conjugated secondary antibody and DAPI.  
Cyt c, cytochrome c. C, controls. One representative of three different experiments performed is shown. Scale 
bar, 5 μ m.
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and CHOP proteins are expressed at almost undetectable levels in both cells lines. δ -TT treatment induced: 1) the 
expression of these transcription factors, as evidenced by the appearance of the red fluorescence; 2) their nuclear 
localization, as shown by the overlapping staining between TRITC-conjugated antibodies and DAPI (Fig. 4b).
Figure 4. δ-TT increases the expression of ER stress-related proteins in BLM and A375 melanoma cells. 
(a) As a positive control, BLM cells were treated with thapsigargin (TG, 1 μ M, for 1–24 h), known to activate 
ER stress. Melanoma cells (both BLM and A375) were treated with δ -TT (20 μ g/ml) for 1–24 h. Western blot 
analysis was performed with the following antibodies against GRP78/BiP (1:1,500), PERK (1:1,500), p-eIF2α 
(1:1,000), eIF2α (1:1,000), IRE1α (1:1,000), ATF4 (1:1,000), CHOP (1:1,000), ERO1α (1:1,500), PDI (1:1,000), 
caspase-4 (1:1,000). β -actin expression was evaluated as a loading control. One representative of three different 
experiments, for each of the analyses performed, is shown. (b) Melanoma cells were treated with δ -TT  
(20 μ g/ml) for 18 h. The intracellular localization of the ER stress-related apoptosis markers ATF4 and CHOP 
was evaluated by immunofluorescence analysis with the primary antibodies anti-ATF4 (1:100) or anti-CHOP 
(1:1,000), followed by the TRITC-conjugated secondary antibody and DAPI. C, controls. One representative of 
three different experiments performed is shown. Scale bar, 5 μ m.
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δ-TT increases the expression of ER stress-related mRNAs in melanoma cells. To confirm the 
results obtained from the Western blot analyses, we investigated the effects of δ -TT (20 μ g/ml) on the gene expres-
sion of CHOP and IRE1α (representative of the two major ER stress-related pathways), measured by real-time 
RT-PCR. Based on the data on protein expression, the mRNAs levels of the two markers were analyzed after 18 h 
of treatment with δ -TT. We found that, at this time interval, the mRNA levels of both CHOP and IRE1α were 
significantly increased, both in BLM and A375 cells (Fig. 5).
ER stress mediates the δ-TT-induced apoptotic cell death in melanoma cells. Data so far reported 
suggest that ER stress might be involved in the proapoptotic activity of δ -TT. To confirm this hypothesis, BLM 
and A375 cells were pretreated with 25 μ M salubrinal (an ER stress-induced apoptosis inhibitor, due to its inhib-
itory activity on eIF2α dephosphorylation)37, 1 h before δ -TT. Cell viability and caspase-3 activation were then 
investigated by means of MTT assay and Western blotting, respectively. Figure 6a shows that, as expected, cell 
viability was significantly decreased after δ -TT treatment; salubrinal alone did not affect cell viability (24 h). 
Pretreatment with salubrinal significantly reverted the cytotoxic effect of δ -TT, both in BLM and in A375 cells. 
These results were confirmed by caspase-3 cleavage (at 24 and 18 h in BLM and A375 cells, respectively) (Fig. 6b). 
It must be underlined that the cytotoxic effect of δ -TT was significantly, but not completely, reverted by salubri-
nal. This suggests that different apoptotic mechanisms, in addition to the PERK/p-eIF2α /ATF4/CHOP pathway, 
might be involved in the antitumor activity of δ -TT, particularly in A375 cells at this time interval (24 h). In sup-
port to this hypothesis, Fig. 6b shows that the expression levels of cleaved caspase-3 are still high in this cell line 
at 24 h of treatment.
Growth-inhibitory activity of δ-TT on melanoma xenografts in nude mice. Based on the signif-
icant antitumor activity of δ -TT on melanoma cells in vitro, preclinical experiments were performed on animal 
models. Since δ -TT exerted a similar proapoptotic activity on both melanoma cell lines (e.g. independently on 
their mutation status), we selected the A375 cell line to perform these experiments. A375 cells were subcutane-
ously inoculated in 6 months-old female immunodeficient CD1-nu/nu mice. At 10 days after tumor injection, 
mice were orally treated with δ -tocotrienol extract in olive oil (100 mg/kg daily, 5 days/week) up to 35 days, while 
Figure 5. δ-TT increases the expression of ER stress-related mRNAs in BLM and A375 melanoma cells. 
Melanoma cells were treated with δ -TT (20 μ g/ml) for 18 h. The expression levels of CHOP and IRE1α mRNAs 
were evaluated by quantitiative RT-PCR, utilizing specific sets of primers. Four replicates were performed for 
each experimental point and the experiments were repeated four times. * p < 0.05 vs C, controls.
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controls received olive oil only. Tumor volumes were calculated at the beginning of the treatment, at 3, 6, 12, 18, 
24, 30, and 35 days, the end of the treatment: a significant reduction was observed at 24–35 days, comparing the 
δ -TT-treated group with the control group (Fig. 7a). At the end of the experiments (day 35) a significant decrease 
(60.6%) of tumor weight was observed in δ -TT-treated vs. control mice, as evaluated by Mann-Whitney test 
(Fig. 7b). The incidence of tumor progression was also determined by Kaplan-Meier analysis, evidencing a delay 
of tumor progression in δ -TT-treated group (Fig. 7c). In control mice tumor progression occurred 6 days after 
treatment with vehicle and progressively increased to 100% on day 12 (Fig. 7c). In contrast, in δ -TT-treated mice, 
tumor progression occurred at day 18 and progressively increased to 100% on day 30 (Fig. 7c). The mean time 
to tumor progression was significantly delayed in δ -TT-treated mice (24 days; 95%CI 9.23 to 12.37) with respect 
to controls (10.8 days; 95%CI 20.96 to 27.04). The curve reporting the incidence of tumor progression over time 
during δ -TT treatment significantly differed from controls (Logrank test; P < 0.0001). Mice treated with vehicle 
developed 3.30 fold-higher probability to develop tumor progression than mice treated with δ -TT (HR = 3.39; 
95%CI 1.19 to 9.64; P < 0.0001, Fig. 7d).
Discussion
Vitamin E-derived TTs exert healthy effects in various chronic pathologies, such as cardiovascular and neurode-
generative diseases, based on their antiinflammatory and antioxidant properties. TTs, the δ -TT and γ -TT isomers 
in particular, were also shown to exert anticancer activity in different tumor models. On the other hand, evidence 
so far available about the antitumor effects of TTs on melanoma, and the molecular mechanisms underlying this 
activity, are still scanty.
We sought to investigate whether δ -TT might exert a cytotoxic/proapoptotic effect in two human melanoma 
cells lines (BLM and A375) and to dissect the molecular mechanisms underlying this activity. The data obtained 
from in vitro studies were then translated into in vivo experiments. For these studies we selected BLM and A375 
human melanoma cell lines, representative of the most frequent genetic mutations in melanomas (NRAS and 
V600E BRAF in BLM and A375 cells, respectively).
Figure 6. ER stress mediates the δ-TT-induced apoptotic cell death in BLM and A375 melanoma cells. 
Melanoma cells were pretreated with salubrinal (25 μ M), an ER stress-induced apoptosis inhibitor 1 h before 
δ -TT treatment (20 μ g/ml). Cell viability and caspase-3 activation were investigated by means of MTT assay 
(24 h treatment) (a) and Western blot analysis (18 and 24 h treatment) (b). In Western blot analysis, β -actin 
expression was evaluated as a loading control. Each experiment was repeated three times. Data in (a) represent 
mean values ± SEM and were analyzed by Bonferroni’s test after one-way analysis of variance. * p < 0.005 vs 
controls. p < 0.005 vs δ -TT.
www.nature.com/scientificreports/
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We found that δ -TT, significantly and dose-dependently, reduces cell viability in both melanoma cell lines; 
importantly, the tocotrienol did not exert toxic effects on normal melanocytes at any of the doses utilized, sug-
gesting that it may act by selectively targeting cancerous cells. We confirmed the δ -TT cytotoxic activity on both 
BLM and A375 cells by the reduction in the viability of colony-forming cells and the induction of cell death by the 
Trypan blue-exclusion assay. We further demonstrated that δ -TT triggers the intrinsic apoptosis pathway as evi-
denced by the increased Bax/Bcl-2 ratio, cytochrome c release from mitochondria and cleavage of procaspase-3 
and its downstream target PARP in both cell lines.
These results demonstrate that δ -TT exerts a significant antiproliferative/proapoptotic effect on human mela-
noma cells; importantly the tocotrienol is devoid of any cytotoxic activity on normal melanocytes.
In line with our observations, δ -TT was reported to induce cell cycle arrest and apoptosis in human melanoma 
cells38,39, while γ -TT was shown to induce apoptosis, suppress invasion and sensitize cells to chemotherapeutic 
drugs40. Finally, the antitumor activity of TTs was observed in B16 murine melanoma cells41–43.
The observation that δ -TT is associated with a significant proapoptotic effect in melanoma cells is in agree-
ment with the reported antitumor activity of TTs (mainly δ -TT and γ -TT) in different types of tumors19,33,35,44.
To get insights into the molecular mechanisms involved in the proapoptotic activity of TTs in melanoma cells, 
we focused our attention on the ER stress pathways. As outlined in the Introduction, in conditions of severe ER 
stress, the chaperone protein BiP dissociates from the ER membrane and triggers the activation of the three main 
protein sensors (PERK, IRE1α and ATF6); each of these proteins is coupled with a cytosolic pathway converging 
on apoptosis26,28. We found that, in both BLM and A375 melanoma cell lines, δ -TT increases the expression of 
BiP and of the two sensors PERK and IRE1α . In line with this observation, δ -TT also increased the expression 
levels of p-eIF2α and the expression/activation (cytoplasmic-to-nuclear localization) of the transcription factors 
ATF4 and CHOP. p-eIF2α , ATF4 and CHOP are known to be induced by PERK; in addition, CHOP was shown 
to be activated by IRE1α through the p38MAPK pathway26,28. In agreement with these observations we found 
Figure 7. δ-TT inhibits the growth and progression of A375 melanoma xenografts in nude mice. Mice 
xenografted with A375 cells were treated orally with δ -TT (100 mg/kg in olive oil, daily, 5 days/week) for 
different time intervals, up to 35 days, starting when the tumor volume reached 0.5–0.8 mm3. (a) Tumor volume 
was assessed at the beginning of the treatment, at 3, 6, 12, 18, 24, 30, and 35 days, the end of the treatment.  
* p < 0.001 vs C, controls. (b) Tumor weight was assessed at the end of the treatment. * p < 0.0001 vs C, controls. 
(c) Graphical representation of tumor progression incidence, determined by Kaplan-Meier analysis, over the 
time upon δ -TT treatment. (d) The curves reported in (c) were compared by the Logrank test to evaluate the 
respective hazard ratio values, 95% confidence in hazard ratio and significance values. C, controls.
www.nature.com/scientificreports/
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that the expression of CHOP and IRE1α was increased by δ -TT also at the mRNA level. Taken together, these data 
indicate that both the PERK and IRE1α signaling branches are triggered in melanoma cells after δ -TT treatment, 
converging to the activation of CHOP, the key mediator of the ER stress-related apoptosis.
We observed that δ -TT increases the expression of ERO1α in A375, but not in BLM, melanoma cells; on the 
other hand the expression of PDI was unaffected by the treatment in both cell lines. ERO1α , a direct target of 
CHOP, is involved in the hyperoxidation of the ER environment through generation of ROS and in the protein 
folding processes through activation of PDI. To explain our results, we suggest that, in A375 cells, the increase of 
ERO1α levels might reflect an overproduction of ROS, contributing to cell stress45. On the other hand, the lack of 
ERO1α induction in BLM cells might indicate a reduced activity of PDI in restoring protein folding, leading to an 
ER stressful condition that cannot be attenuated.
Caspase-4 is the initiator caspase directly involved in the ER stress-induced apoptosis28 through the activation 
of the effector caspase-3. Different ER stressors lead to the release of ER Ca2+ stores, leading to the activation of 
calpain28 that, in turn, cleaves caspase-4; caspase-4 can also be activated by IRE1α in conditions of severe ER 
stress. Here, we found that δ -TT induced the cleavage of caspase-4 in both BLM and A375 melanoma cell lines.
These data demonstrate that, in melanoma cells, δ -TT triggers cell death and activates the ER stress-related 
pathways. ER stress-related apoptosis markers, particularly the PERK/p-eIF2α /ATF4/CHOP and IRE1α 
branches, were previously demonstrated to induce cell death through the activation of the intrinsic apoptosis 
pathway26,28. To verify whether the proapoptotic activity of δ -TT might be mediated by the ER stress process, we 
evaluated the effects of salubrinal on the activity of the tocotrienol on melanoma cell viability and on caspase-3 
activation. Salubrinal is an inhibitor of the ER stress-related apoptosis pathways, due to its inhibitory effect on the 
eIF2α dephosphorylation37. Thus, salubrinal is considered a legitimate candidate drug to counteract the effects of 
cytotoxic compounds that induce ER stress. Our data demonstrate that, in BLM and A375 cells, salubrinal signif-
icantly counteracts the cytotoxic activity of δ -TT as evaluated in terms of cell viability and caspase-3 activation. 
However, in both cell lines, the reversal of the apoptotic activity of δ -TT was only partial. This may be explained, 
at least partially, by the fact that salubrinal targets only the PERK branch of the ER stress.
Based on the in vitro results, we sought to confirm the efficacy of δ -TT against melanoma growth in preclinical 
models of A375 melanoma cell xenografts in nude mice. We observed that δ -TT induces a significant reduction 
in tumor volume at different times of treatment as well as in tumor mass at the end of the treatments; importantly, 
δ -TT also significantly delayed tumor progression. No systemic toxicity was observed, supporting the above dis-
cussed lack of cytotoxicity of δ -TT on normal human melanocytes.
The data here reported demonstrate that δ -TT exerts a significant proapoptotic activity on human mela-
noma cells (while sparing normal melanocytes), both in vitro and in vivo, and that this activity is mediated, at 
least partially, by the induction of the ER stress process. To our knowledge, the association of the ER stress with 
the apoptotic activity of tocotrienols has been demonstrated only in breast cancer cells, so far46,47. On the other 
hand, the ER stress branches have been shown to be involved in the antitumor activity of a variety of natural 
compounds48–51.
ER stress-mediated pathways were proved to represent a relevant target for melanoma treatment52; moreover, 
drugs that specifically act by targeting the ER stress were shown to improve the efficacy of chemotherapeutic 
drugs53. Finally, the biosafety of TTs was previously reported12. Moreover, clinical trials are at present ongoing 
with the aim to evaluate the safety, biodisponibility and efficacy of TTs in different tumors (pancreatic, lung and 
ovarian cancers), given either alone or in association with standard treatments (ClinicalTrials.gov). Based on 
these observations, our results support the evidence that δ -TT, through its ability to trigger the ER stress, might 
be considered as an effective compound for novel chemopreventive/therapeutic (e.g. combinational) strategies 
for melanoma.
Methods
Cell cultures. The human BLM melanoma cell line (NRAS mutated) was provided by Dr. G.N. van Muijen 
(Department of Pathology, Radbound University Nijmegen Medical Center, Nijmegen, The Netherlands). This 
cell line is a subline of BRO melanoma cells isolated from lung metastases after subcutaneous inoculation of 
nude mice with BRO cells54. This cell line was previously utilized in the authors’ laboratory55. The human A375 
melanoma cell line (V600E BRAF mutated) was from American Type Culture Collection (ATCC, Manassas, VA, 
USA). Human primary melanocytes were provided by Dr. F. Crovato (Regional Reference Centre for Human 
Epidermis in vitro Culture and Bank for Tissue Crypreservation, Niguarda Hospital, Milano, Italy). Original 
stocks of cells were stored frozen in liquid nitrogen; after resuscitation, cells were kept in culture for no more 
than 10–12 weeks. BLM and A375 melanoma cells, and human melanocytes were routinely cultured in DMEM 
medium supplemented with 10% FBS, glutamine and antibiotics. Cells were cultured in humidified atmosphere 
of 5% CO2/95% air at 37 °C.
Materials. For Western blotting analysis the following primary antibodies were utilized: cleaved caspase-3 
(Asp175; clone 5A1E), PARP, BiP (clone C50B12), PERK (clone D11A8), p-eIF2α (clone D9G8), eIF2α (clone 
D7D3), IRE1α (clone 14C10), ATF4 (clone D4B8), CHOP (clone L63F7), ERO1α , PDI (clone C81H6) and 
caspase-4 (Cell Signaling Technology Inc., Boston, MA); Bcl-2 (clone C-2), Bax (clone 6A7) and cytochrome c 
(clone 7H8) (Santa Cruz Biotecnology Inc., Santa Cruz, CA). Horseradish-peroxidase-conjugated secondary 
antibody and enhanced chemiluminescence reagents were from GE Healthcare, Life Sciences (Milano, Italy). For 
immunofluorescence analysis the following primary antibodies were utilized: ATF4 (clone D4B8), CHOP (clone 
L63F7) and cytochrome c (clone 7H8) (Santa Cruz Biotechnology Inc.). FITC- or TRITC-conjugated secondary 
antibodies Alexa Fluor 488 and 594 were from Molecular Probes Inc. (Eugene, OR). Salubrinal (the selective 
eIF2α dephosphorylation inhibitor), thapsigargin (the SERCA inhibitor), and all analytical grade solvents were 
from Sigma-Aldrich (Milano, Italy).
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δ-TT purification. HPLC analysis and isolation of δ -TT were done using a LC-940 Liquid Cromatography 
instrument (Varian, Leinì, Italy) equipped with: binary pump system (pump head volume V = 10 ml, eluent 
flow range: 0.3–25 ml/min), autosampler (5 ml vials, injection volume 5–4000 ml), scale up module, photodiode 
array (wavelengths range: λ = 200–400 nm, set at λ = 290 nm), automatic fraction collector. Separations were 
conducted using an analytical reversed phase Kinetex® column (5 μ m C18 100 Å, 100 × 4.6 mm, Phenomenex, 
Castel Maggiore, Italy), eluent flow 2 ml/min (injection volume 5 μ l). For the isolation of δ -TT at semipreparative 
scale, a Kinetex AXIA column (5 μ m C18 100Å, 100 × 21.5 mm, Phenomenex, Castel Maggiore, Italy) was used. 
Eluent: acetonitrile 100%, flow: 20 ml/min, run time: 10 min, injection volume: 4000 μ l. δ -TT was isolated from: 
a) a commercial palm oil (Elaeis guineensis) fraction enriched in tocotrienols/tocopherols (Gold Tri E 70% w/w, 
Golden Hope Bioganic, Selangor, Malaysia), for in vitro studies; b) a commercial extract of Annatto (Bixa orel-
lana) seeds (DeltaGold, American River Nutrition Inc., Hadley, MA ), for in vivo studies. a) The palm oil fraction 
was extracted with acetonitrile (1:1 vol/vol), the solvent phase centrifuged (6000 rpm, d = 15 cm, t = 5 min) and 
evaporated under reduced pressure (endpoint 1 mbar) at room temperature. The oily extract (100 mg, OE) was 
dissolved in HPLC grade methanol (5 ml) injected as above described. Fractions were collected in time slice mode 
in the RT window 2.3–2.5 min. To eliminate the contamination from the partially overlapping peak due to β - and 
γ -TT, all fractions of interest were pooled together, acetonitrile evaporated, the resulting residue diluted again 
in methanol and reinjected until a purity of at least > 95% was achieved. The average recovery yield was around 
10 mg per 100 mg of OE. Aliquots of 50 mg were diluted in dimethylsulfoxide at the concentration of 50 mg/ml 
and stored at − 20 °C. b) Annatto extract was processed as in (a) with minor modifications. deltaGold (200 mg) 
was extracted with methanol (5 ml), centrifuged and the supernatant injected and processed as in (a). Aliquots of 
purified δ -TT were pooled together and diluted in olive oil.
MTT viability assay. BLM and A375 melanoma cells were seeded at a density of 3 × 104 cells/well and 
human melanocytes at a density of 104 cells/well in 24-well plates. After 24 h, cells were treated with different 
doses of δ -TT (5–20 μ g/ml) for 24 or 48 h. The medium was changed with MTT solution (0.5 mg/ml) in DMEM 
without phenol red and FBS; cells were incubated at 37 °C for 15–45 min and violet precipitate was dissolved with 
isopropanol. Absorbance at 550 nm was measured through an EnSpire Multimode Plate reader (PerkinElmer, 
Milano, Italy).
To assess the ER-stress involvement in the δ -TT-induced cell death, BLM and A375 cells were seeded at a 
density of 3 × 104 cells/well in 24-well plates, in DMEM complete medium. After 48 h, cells were treated with salu-
brinal (25 μ M). After 1 h treatment, 20 μ g/ml of δ -TT or vehicle were added to each well. After 24 h, cell viability 
was analyzed as describe above.
Trypan blue exclusion assay. BLM and A375 cells were plated (5 × 104 cells/dish) in 6-cm dishes. After 
48 h cells were treated with different doses of δ -TT (5, 10, 15 or 20 μ g/ml) for 24 h. Adherent and floating cells 
were then harvested, stained with Trypan blue 0.4% (1:1 v/v) and counted by Luna automated cell counter (Logos 
Biosystems, Annandale, VA), discriminating between total, viable and dead cells.
Colony-formation assay. BLM and A375 cells were seeded (100–250 cells/well, depending on the cell type) 
in 6-well plates. After 48 h, cells were treated with δ -TT (20 μ g/ml) for 72 h and then cultured for 7–10 days. 
Colonies were fixed with 70% methanol and stained with Crystal Violet 0.15%. Images of stained colonies were 
captured by a Nikon photocamera.
Western blot assay. To investigate the effects of δ -TT on the expression of apoptosis and ER stress-related 
proteins, BLM and A375 cells were plated (5 × 105 cells/dish) in 10-cm dishes, for 48 h. Cells were then treated 
with δ -TT (20 μ g/ml) for 1–48 h. Adherent and floating cells were harvested and lysed in RIPA buffer; protein 
preparations (30–40 μ g) were resuspended in reducing Sample buffer (Bio-Rad Laboratories, Segrate, Mi, Italy) 
and heated at 95 °C for 5 min. Following electrophoretic separation by SDS-PAGE, proteins were transferred 
onto nitrocellulose membrane. After blocking, membranes were incubated with the primary antibodies against 
cleaved (activated) caspase-3, PARP, Bcl-2, Bax, BiP, PERK, p-eIF2α , eIF2α , IRE1α , ATF4, CHOP, ERO1α , PDI, 
caspase-4. Detection was done using horseradish peroxidase-conjugated secondary antibodies, and enhanced 
chemiluminescence ECL-Prime reagents. As a positive control of ER stress induction, BLM cells were treated 
with 1 μ M thapsigargin, a selective inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). The 
expression of ER stress-related proteins was analyzed as above.
To assess the ER-stress involvement in the δ -TT-induced apoptosis, BLM and A375 cells were seeded at a 
density of 5 × 105 cells/dish. After 48 h, cells were treated with salubrinal (25 μ M). After 1 h of treatment, 20 μ g/ml 
of δ -TT were added to each well. After 24 h, the expression levels of cleaved caspase-3 were assessed by Western 
blot assay as described above.
Immunofluorescence assay. To assess the localization of ER stress markers, BLM and A375 cells were 
seeded at 3 × 104 cells/well on polylysine-coated 13-mm diameter coverslips. After 48 h, cells were treated with 
δ -TT (20 μ g/ml) for 18 h, fixed and stained with ATF4 or CHOP antibodies, followed by TRITC-conjugated sec-
ondary antibody and DAPI.
To verify the release of cytochrome c from mitochondria, BLM and A375 cells were seeded as described, fol-
lowed by 24 h treatment with δ -TT. Cells were then incubated for 30 min with Mitotracker (250 nM) (Molecular 
Probes Inc.), fixed and stained with cytochrome c antibody, followed by FITC-conjugated secondary antibody 
and DAPI. Labeled cells were examined under a Zeiss Axiovert 200 microscope with a 63x/1.4 objective lens 
linked to a Coolsnap Es CCD camera (Roper Scientific-Crisel Instruments, Roma, Italy).
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:30502 | DOI: 10.1038/srep30502
Quantitative PCR. To investigate the effects of δ -TT on the expression of ER stress-related (CHOP and 
IRE1α ) mRNAs, BLM and A375 cells were plated (1.5 × 105 cells/well) in 6-well plates, for 48 h. Cells were then 
treated with δ -TT (20 μ g/ml) for 18 h. Adherent and floating cells were harvested and total RNA was extracted 
using TRIzol according to the manufacturer’s instructions (Invitrogen Life Technology, Inc., Paisley, UK). RNA 
pellet concentrations were assessed spectrophotometrically using Nanodrop 2000 (Thermo Fisher Scientific, 
Waltham, MA) (OD 260/280).
Specific sets of primers for CHOP and IRE1α cDNAs were designed and synthesized (Sigma-Aldrich), accord-
ing to Chen and coworkers56. Real-time PCR was performed as previously described57. Briefly, real-time DNA 
amplification was performed in CFX96 Bio-Rad using 20 μ l of total volume. The efficiency of each set of primers 
was evaluated in preliminary experiments and it was found close to 100% for target genes and for the housekeep-
ing gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Total RNA (600 ng) was retrotranscribed using 
the IScript Supermix kit (Bio-Rad), according to the manufacturer’s protocol. The amplification was carried out 
on 2.5 ng of total cDNA using SYBR chemistry (iTAQ Universal SYBR green supermix, Bio-Rad) according to the 
manufacturer’s protocol. Real-time PCR was run according to the following protocol: an initial step of 30 sec at 
95 °C followed by 40 cycles of 5 sec at 95 °C and 30 sec at 60 °C. A dissociation stage with a melt curve analysis was 
also performed. Four replicates were performed for each experimental point and experiments were repeated four 
times. Gene expression was quantified using the comparative threshold-cycle (DDCt) method considering that 
the targets and the reference genes have the same amplification efficiency (near to 100%).
Mouse melanoma xenografts. Immunodeficient female CD1-nu/nu mice, at 6 weeks of age, were pur-
chased from Charles River (Milano, Italy). All the experiments were approved and were carried out in accordance 
with the relevant guidelines and regulations established by the University of L’Aquila (Medical School and Science 
and Technology School Board Regulations, complying with the Italian government regulation n.116 January 27 
1992 for the use of laboratory animals) which is in line with ARRIVE guidelines58. Before manipulations, all mice 
were anesthetized with a mixture of ketamine (25 mg/ml) and xylazine (5 mg/ml) and received subcutaneous 
flank injections (2 each) of 106 A375 cells mixed with Matrigel (Beckton Dickinson Labware, Bedford, MA, USA). 
At 10 days after tumor injection, mice with tumor volume 0.5–0.8 cm3 were divided into two groups receiving 
olive oil (10 tumors) or δ -TT (100 mg/kg in olive oil, daily; 10 tumors) by oral gavage, 5 days/week. At the end 
of the experiments (35 days after the start of treatments) animals were sacrificed by carbon dioxide inhalation 
and tumors were surgically removed. Tumor growth was assessed at the beginning of the treatment, at 3, 6, 12, 
18, 24, 30 and at 35 days by measuring tumor diameters with a Vernier caliper (length × width). The volume of 
the tumor was expressed in mm3 according to the formula 4/3 π r3. Tumor weight was calculated according to 
the formula: TW (mg) = (d2 × D)/2, where d and D are the shortest and longest diameters, respectively59. Tumor 
progression (TP) was defined as an increase of tumor volume greater than 100% with respect to baseline; time to 
tumor progression (TTP). To evaluate treatment toxicity, serial bodyweight measurements were performed every 
3–4 days during treatments.
Statistical analysis. When appropriate, data were analyzed by Bonferroni’s test, after one-way analysis of 
variance. The incidence of tumor progression was determined by Kaplan–Meier analysis and a Gehan’s gener-
alized Wilcoxon test. Two Kaplan–Meier curves were compared by the Logrank test. All tests were two-sided 
and were determined by Monte Carlo significance. P values < 0.05 were considered statistically significant. SPSS 
(statistical analysis software package, IBM Corp., Armonk, NY, USA) version 10.0 and StatDirect (version. 2.3.3, 
StatDirect Ltd, Altrincham, Manchester, UK) were used for statistical analysis and graphical presentation.
References
1. Higgins, H. W., 2nd, Lee, K. C., Galan, A. & Leffell, D. J. Melanoma in situ: Part I. Epidemiology, screening, and clinical features. J 
Am Acad Dermatol 73, 181–190 (2015).
2. Jilaveanu, L. B., Aziz, S. A. & Kluger, H. M. Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 27, 
614–625 (2009).
3. Vujic, I. et al. Mutant NRASQ61 shares signaling similarities across various cancer types–potential implications for future therapies. 
Oncotarget 5, 7936–7944 (2014).
4. Niezgoda, A., Niezgoda, P. & Czajkowski, R. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted 
Therapy and Immunotherapy. Biomed Res Int 2015, 851387 (2015).
5. Larkin, J., Hodi, F. S. & Wolchok, J. D. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J 
Med 373, 1270–1271 (2015).
6. Hao, M. et al. Advances in targeted therapy for unresectable melanoma: new drugs and combinations. Cancer Lett 359, 1–8 (2015).
7. Swinney, D. C. & Anthony, J. How were new medicines discovered? Nat Rev Drug Discov 10, 507–519 (2011).
8. Hosseini, A. & Ghorbani, A. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed 5, 84–97 
(2015).
9. Scarpa, E. S. & Ninfali, P. Phytochemicals as Innovative Therapeutic Tools against Cancer Stem Cells. Int J Mol Sci 16, 15727–15742 
(2015).
10. Shanmugam, M. K., Kannaiyan, R. & Sethi, G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the 
prevention and treatment of cancer. Nutr Cancer 63, 161–17 (2011).
11. Tete, S. et al. Nutrition and cancer prevention. Int J Immunopathol Pharmacol 25, 573–581 (2012).
12. Ahsan, H., Ahad, A., Iqbal, J. & Siddiqui, W. A. Pharmacological potential of tocotrienols: a review. Nutr Metab (Lond) 11, 52 (2014).
13. Peh, H. Y., Daniel Tan, W. S., Liao, W. & Fred Wong, W. S. Vitamin E therapy beyond cancer: tocopherol versus tocotrienol. 
Pharmacol Ther, doi: 10.1016/j.pharmthera.2015.12.003 (2015).
14. Kline, K., Lawson, K. A., Yu, W. & Sanders, B. G. Vitamin E and cancer. Vitam Horm 76, 435–461 (2007).
15. Yano, T., Sato, A., Sekine, M., Virgona, N. & Ota, M. Redox-inactive analogue of tocotrienol as a potential anti-cancer agent. 
Anticancer Agents Med Chem 13, 496–501 (2013).
16. Nesaretnam, K. & Meganathan, P. Tocotrienols: inflammation and cancer. Ann N Y Acad Sci 1229, 18–22 (2011).
17. Kannappan, R., Gupta, S. C., Kim, J. H. & Aggarwal, B. B. Tocotrienols fight cancer by targeting multiple cell signaling pathways. 
Genes Nutr 7, 43–52 (2012).
www.nature.com/scientificreports/
13Scientific RepoRts | 6:30502 | DOI: 10.1038/srep30502
18. Ling, M. T., Luk, S. U., Al-Ejeh, F. & Khanna, K. K. Tocotrienol as a potential anticancer agent. Carcinogenesis 33, 233–239 (2012).
19. Lim, S. W., Loh, H. S., Ting, K. N., Bradshaw, T. D. & Zeenathul, N. A. Cytotoxicity and apoptotic activities of alpha-, gamma- and 
delta-tocotrienol isomers on human cancer cells. BMC Complement Altern Med 14, 469 (2014).
20. Wang, M. & Kaufman, R. J. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature 529, 326–335 
(2016).
21. Schonthal, A. H. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol 85, 653–666 
(2013).
22. Foufelle, F. & Fromenty, B. Role of endoplasmic reticulum stress in drug-induced toxicity. Pharmacol Res Perspect 4, e00211 (2016).
23. Halperin, L., Jung, J. & Michalak, M. The many functions of the endoplasmic reticulum chaperones and folding enzymes. IUBMB 
Life 66, 318–326 (2014).
24. Parmar, V. M. & Schroder, M. Sensing endoplasmic reticulum stress. Adv Exp Med Biol 738, 153–168 (2012).
25. Sano, R. & Reed, J. C. ER stress-induced cell death mechanisms. Biochim Biophys Acta 1833, 3460–3470 (2013).
26. Hiramatsu, N., Chiang, W. C., Kurt, T. D., Sigurdson, C. J. & Lin, J. H. Multiple Mechanisms of Unfolded Protein Response-Induced 
Cell Death. Am J Pathol 185, 1800–1808 (2015).
27. Maurel, M. et al. Controlling the unfolded protein response-mediated life and death decisions in cancer. Semin Cancer Biol 33, 
57–66 (2015).
28. Schonthal, A. H. Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Scientifica (Cairo) 2012, 85751 
(2012).
29. Bu, Y. & Diehl, J. A. PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. J Cell Physiol, 
doi: 10.1002/jcp.25336 (2016).
30. Ivanova, E. A. & Orekhov, A. N. The Role of Endoplasmic Reticulum Stress and Unfolded Protein Response in Atherosclerosis. Int J 
Mol Sci 17, doi: 10.3390/ijms17020193 (2016).
31. Keestra-Gounder, A. M. et al. NOD1 and NOD2 signalling links ER stress with inflammation. Nature 532, 394–397 (2016).
32. Pereira, D. M., Valentao, P., Correia-da-Silva, G., Teixeira, N. & Andrade, P. B. Translating endoplasmic reticulum biology into the 
clinic: a role for ER-targeted natural products? Nat Prod Rep 32, 705–722 (2015).
33. Comitato, R. et al. Tocotrienols activity in MCF-7 breast cancer cells: involvement of ERbeta signal transduction. Mol Nutr Food Res 
54, 669–678 (2010).
34. Tran, A. T., Ramalinga, M., Kedir, H., Clarke, R. & Kumar, D. Autophagy inhibitor 3-methyladenine potentiates apoptosis induced 
by dietary tocotrienols in breast cancer cells. Eur J Nutr 54, 265–272 (2015).
35. Pierpaoli, E. et al. Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic 
mice. Carcinogenesis 34, 1352–1360 (2013).
36. Winther, A. M. et al. Critical roles of hydrophobicity and orientation of side chains for inactivation of sarcoplasmic reticulum 
Ca2 + -ATPase with thapsigargin and thapsigargin analogs. J Biol Chem 285, 28883–28892 (2010).
37. Matsuoka, M. & Komoike, Y. Experimental evidence shows salubrinal, an eIF2alpha dephosphorylation inhibitor, reduces 
xenotoxicant-induced cellular damage. Int J Mol Sci 16, 16275–16287 (2015).
38. Fernandes, N. V., Guntipalli, P. K. & Mo, H. B. d-delta-Tocotrienol-mediated Cell Cycle Arrest and Apoptosis in Human Melanoma 
Cells. Anticancer Res 30, 4937–4944 (2010).
39. de Mesquita, M. L. et al. Cytotoxicity of delta-tocotrienols from Kielmeyera coriacea against cancer cell lines. Bioorgan Med Chem 
19, 623–630 (2011).
40. Chang, P. N. et al. Evidence of gamma-Tocotrienol as an Apoptosis-Inducing, Invasion-Suppressing, and Chemotherapy Drug-
Sensitizing Agent in Human Melanoma Cells. Nutr Cancer 61, 357–366 (2009).
41. Fu, J. Y. et al. Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration. J Controlled Rel 154, 
20–26 (2011).
42. Choi, B., Heo, J. H., Kwon, H. J., Lee, E. S. & Sohn, S. Tocotrienols enhance melanosome degradation through endosome docking/
fusion proteins in B16F10 melanoma cells. Food Funct 4, 1481–1488 (2013).
43. Ng, L. T. et al. Anti-melanogenic effects of delta-tocotrienol are associated with tyrosinase-related proteins and MAPK signaling 
pathway in B16 melanoma cells. Phytomedicine 21, 978–983 (2014).
44. Viola, V. et al. Mitochondrial-dependent anticancer activity of delta-tocotrienol and its synthetic derivatives in HER-2/neu 
overexpressing breast adenocarcinoma cells. Biofactors 39, 485–493 (2013).
45. Laurindo, F. R., Pescatore, L. A. & Fernandes Dde, C. Protein disulfide isomerase in redox cell signaling and homeostasis. Free Radic 
Biol Med 52, 1954–1969 (2012).
46. Park, S. K., Sanders, B. G. & Kline, K. Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-
dependent increase in extrinsic death receptor signaling. Breast Cancer Res Treat 124, 361–375 (2010).
47. Patacsil, D. et al. Gamma-tocotrienol induced apoptosis is associated with unfolded protein response in human breast cancer cells. 
J Nutr Biochem 23, 93–100 (2012).
48. Rizzi, F. et al. Polyphenon E(R), a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of 
immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis. Carcinogenesis 35, 828–839 (2014).
49. Zhai, B. et al. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of 
Endoplasmic Reticulum Stress. PLoS One 10, e0138485 (2015).
50. Choi, J. Y. et al. Podophyllotoxin acetate triggers anticancer effects against non-small cell lung cancer cells by promoting cell death 
via cell cycle arrest, ER stress and autophagy. Int J Oncol 47, 1257–1265 (2015).
51. Kim, B. et al. Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical 
cancer cells. Mol Carcinog 55, 918–928 (2016).
52. Hassan, M. et al. Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma 
treatment. World J Exp Med 5, 206–217 (2015).
53. Mihailidou, C., Chatzistamou, I., Papavassiliou, A. G. & Kiaris, H. Improvement of chemotherapeutic drug efficacy by endoplasmic 
reticulum stress. Endocr Relat Cancer 22, 229–238 (2015).
54. Van Muijen, G. N. et al. Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude 
mice. Clin Exp Metastasis 9, 259–272 (1991).
55. Moretti, R. M. et al. Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce 
Melanoma Angiogenesis. Endocrinology 151, 4643–4653 (2010).
56. Chen, S. et al. Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology 322, 78–88 (2014).
57. Marzagalli, M., Casati, L., Moretti, R. M., Montagnani Marelli, M. & Limonta, P. Estrogen Receptor beta Agonists Differentially 
Affect the Growth of Human Melanoma Cell Lines. PLoS One 10, e0134396 (2015).
58. Festuccia, C. et al. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr 
Relat Cancer 16, 401–413 (2009).
59. Gravina, G. L. et al. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin 
function and delaying DNA repair in prostate cancer models. Prostate 74, 852–868 (2014).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 6:30502 | DOI: 10.1038/srep30502
Acknowledgements
This work was supported by Fondazione Banca del Monte di Lombardia (‘Molecular bases for the development of 
chemopreventive and therapeutic strategies in melanoma: estrogen receptor beta, epigenetics, and tocotrienols’) 
(PL) and Comitato Emme Rouge Onlus (‘Evaluation of the antitumor activity of natural compounds tocotrienols 
and possible combination with molecular targeted therapies in melanoma’) (PL).
Author Contributions
M.M.M. was responsible with M.M. for MTT and Trypan blue assays, for immunofluorescence and Western 
blot analyses and for figure preparations. R.M.M. performed the colony formation assays and the statistical 
evaluation of the in vitro data. G.B. performed the purification of δ -TT for both in vitro and in vivo experiments. 
R.C. discussed the results and revised the manuscript. G.L.G. and C.F. supervised the in vivo studies, statistically 
analyzed the data and prepared Figure 6. L.C. performed the real-time RT-PCR experiments. P.L. conceived the 
study, wrote and critically reviewed the manuscript. All authors reviewed the manuscript.
Additional Information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Montagnani Marelli, M. et al. Vitamin E δ-tocotrienol triggers endoplasmic reticulum 
stress-mediated apoptosis in human melanoma cells. Sci. Rep. 6, 30502; doi: 10.1038/srep30502 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
